<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1889-836X</journal-id>
<journal-title><![CDATA[Revista de Osteoporosis y Metabolismo Mineral]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Osteoporos Metab Miner]]></abbrev-journal-title>
<issn>1889-836X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Investigaciones Óseas y Metabolismo Mineral]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1889-836X2022000400002</article-id>
<article-id pub-id-type="doi">10.4321/s1889-836x2022000400002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Teriparatida en el tratamiento sustitutivo del hipoparatiroidismo crónico. A propósito de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Teriparatide in the substitutive treatment of chronic hypoparathyroidism. About a case]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morán-López]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Crespo-Gutiérrez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Puech-de Oriol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital Virgen del Puerto Endocrinología, Diabetes y Nutrición ]]></institution>
<addr-line><![CDATA[Plasencia Cáceres]]></addr-line>
<country>España</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Hospital Virgen del Puerto Medicina Familiar y Comunitaria ]]></institution>
<addr-line><![CDATA[Plasencia Cáceres]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>14</volume>
<numero>4</numero>
<fpage>104</fpage>
<lpage>106</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1889-836X2022000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1889-836X2022000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1889-836X2022000400002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Comunicar la experiencia del uso de teriparatida como tratamiento sustitutivo eficaz para el hipoparatiroidismo crónico.  Material y métodos: Se plantea el caso clínico de un paciente con hipoparatiroidismo crónico postquirúrgico que presentaba previamente difícil control con el tratamiento convencional (sales de calcio y calcitriol) por lo que se inició teriparatida como tratamiento sustitutivo.  Resultados: El paciente presentó valores analíticos del metabolismo fosfocálcico compatibles con la normalidad a partir de la 4º semana de tratamiento con teriparatida, permitiendo la suspensión de los tratamientos previos y manteniendo un buen control pasado un año del cambio de terapia.  Conclusiones: Teriparatida es una opción eficaz para el tratamiento del hipoparatiroidismo crónico. Hemos observado una fase de latencia hasta iniciarse el efecto hormonal por lo que recomendamos monitorización analítica frecuente y desescalar gradualmente el tratamiento con calcitriol y sales de calcio para un adecuado control.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary  Objetive: To report experience in the use of teriparatide as an effective replacement therapy for chronic hypoparathy roidism.  Material and methods: The clinical case of a patient with post&#8208;surgical chronic hypoparathyroidism who previously presented difficult control with conventional treatment (calcium salts and calcitriol) is presented, for which teriparatide was started as a substitute treatment.  Results: The patient presented analytical values of phosphocalcic metabolism compatible with normality from the 4th week of treatment with teriparatide, allowing the suspension of previous treatments and maintaining good control one year after the change in therapy.  Conclusions: Teriparatide is an effective option for treating chronic hypoparathyroidism. We have observed a latency phase until the hormonal effect begins, so we recommend frequent analytical monitoring and gradually reduce treatment with calcitriol and calcium salts for adequate control.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[teriparatida]]></kwd>
<kwd lng="es"><![CDATA[hipoparatiroidismo]]></kwd>
<kwd lng="es"><![CDATA[crónico]]></kwd>
<kwd lng="es"><![CDATA[postquirúrgico]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="en"><![CDATA[teriparatida]]></kwd>
<kwd lng="en"><![CDATA[hipoparatiroidismo]]></kwd>
<kwd lng="en"><![CDATA[crónico]]></kwd>
<kwd lng="en"><![CDATA[postquirúrgico]]></kwd>
<kwd lng="en"><![CDATA[tratamiento]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bollerslev]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rejnmark]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Marcocci]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shoback]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Sitges-Serra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[van Biesen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2015</year>
<volume>173</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>G1-20</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandi]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Bilezikian]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Shoback]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bouillon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Thakker]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Hypoparathyroidism: Summary Statement and Guidelines]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2016</year>
<volume>101</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2273-83</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Dowdy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Keil]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus cal-citriol and calcium]]></article-title>
<source><![CDATA[Clin Endocrinol Metab]]></source>
<year>2003</year>
<volume>88</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>4214-20</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shrader]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2012</year>
<volume>97</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>391-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mannstadt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Vokes]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Brandi]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Ranganath]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2013</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>275-83</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>Agencia española de medicamentos y productos sanitarios</collab>
<source><![CDATA[Informe de Posi-cionamiento Terapéutico de parathor-mona (Natpar®) en el tratamiento del hipoparatiroidismo crónico]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Agencia española de medicamentos y productos sanitarios</collab>
<source><![CDATA[Ficha Técnica NATPAR 50 microgramos/dosis polvo y disolvente para solución inyectable]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcucci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Masi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cianferotti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Giusti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fossi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic hypoparathyroidism and treatment with teriparatide]]></article-title>
<source><![CDATA[Endocrine]]></source>
<year>2021</year>
<volume>72</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>249-59</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
